Phase 4 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the main observation group:
- You have cervical cancer that has come back, spread to other parts of the body, or keeps returning, and you are currently being treated or about to start treatment with a drug called pembrolizumab (either alone or combined with other medicines)
For the early stopping group (in addition to already being in the main observation group):
- You were already enrolled in the main observation group and a decision has been made to stop pembrolizumab for one of these reasons: your cancer fully disappeared after at least 8 treatment cycles; you had a serious immune-related side effect (confirm with trial site for exact grading); you personally prefer to stop due to ongoing or difficult-to-manage side effects; or your cancer partially shrank after at least 8 treatment cycles
- You are willing and able to stop taking pembrolizumab (you may or may not also stop another medicine called bevacizumab at the same time)
Who may not be able to join:
- You have had another type of cancer (other than cervical cancer) that needed active treatment within the last 2 years — though some exceptions apply, such as certain skin cancers or pre-cancerous conditions that were successfully treated (confirm with trial site)
- You have personal, mental health, family, social, or location-related circumstances that might make it hard to follow the study schedule, attend check-up appointments, have scans done, or fill out questionnaires
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: M. Jalving, University Medical Center Groningen
Phone: +31 50 361 2821
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate the progression-free survival (PFS) and compare to the KEYNOTE-826 trial
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.